Showing 3941-3950 of 4677 results for "".
- Stelara Approved for Self-Administrationhttps://practicaldermatology.com/news/20130611-stelara_approved_for_self-administration/2459518/The FDA has approved Stelara (ustekinumab) for self-administration. Previously intended for subcutaneous administration under the supervision of a physician, Stelara can now be administered by patients at home. The drug is approved for the treatment of adult patients with moderate to severe plaque p
- Clark Pharmaceuticals, Ferndale Healthcare Launch DerMendhttps://practicaldermatology.com/news/20130521-clark_pharmaceuticals_ferndale_healthcare_launch_dermend/2459534/Clark Pharmaceuticals partnered with Ferndale Healthcare to launch DerMend Moisturizing Bruise Formula. The formula is predicated on the idea that skin over 50 tends to get thinner and bruises more easily. Blood thinners, even those like low-dose baby aspirin, can cause skin to bruise. DerMend is de
- Anti-bacterial Soap Under FDA Reviewhttps://practicaldermatology.com/news/20130520-anti-bacterial_soap_under_fda_review/2459537/The Food and Drug Administration (FDA) is studying whether triclosan is safe and effective. The FDA's findings could have implications for a $1 billion industry that includes hundreds of anti-bacterial soaps and body washes, particularly in acne washes. The review comes amid recent studies that have
- Georgia Governor Signs AMA Model Legislationhttps://practicaldermatology.com/news/20130520-georgia_governor_signs_ama_model_legislation/2459538/Georgia lawmakers enacted legal protections for physicians engaged in quality and delivery improvement initiatives included in the federal health care reform law. This first-of-its-kind legislation reinforces the concept that medical decisions are made based on a patient's unique medical needs. The
- ASDS Offers Sun-safe Tipshttps://practicaldermatology.com/news/20130520-asds_offers_sun-safe_tips/2459540/The American Society for Dermatologic Surgery (ASDS) partnered with Neutrogena four years ago to create Choose Skin Health, a program that encourages the practice of sun-safe behaviors, including skin cancer prevention through screenings, the regular
- Onset Dermatologics Unveils Anti-Itch Gel for Eczemahttps://practicaldermatology.com/news/20130515-onset_unveils_anti-itch_gel_for_eczema/2459544/A new product for itching associated with eczema is now available from Onset Dermatologics. Aurstat® Anti-Itch Hydrogel is engineered to soothe itching, burning, and pain of atopic dermatitis and various dermatoses, according to the company. The patented hydrogel formulation is alcohol free, fragran
- Corena Therapeutics New to Industryhttps://practicaldermatology.com/news/20130513-corena_therapeutics_new_to_industry/2459546/The emerging Swiss dermatological products company Corena Therapeutics provides safe alternatives to popular treatments. Coresatin, its latest brand of five steroid-free creams, is safely formulated for pediatric patients, according to the
- Thermage Total Tip Available to Dermatologists Nationwidehttps://practicaldermatology.com/news/20130510-thermage_total_tip_available_to_dermatologists_nationwide/2459548/Solta Medical, Inc. launched the Thermage Total Tip 3.0 for face, neck, and body treatments. Targeted, uniform, bulk heating allows dermatologists to treat patients effectively while maintaining patient comfort, according to the company. Thermage
- Outrun The Sun Campaign Launched This Monthhttps://practicaldermatology.com/news/20130502-outrun_the_sun_campaign_launched_this_month/2459552/“Outrun the Sun in May,” a month-long community outreach campaign that encourages people to be both proactive—and active—in terms of skin cancer prevention, launches this month from Outrun the Sun, Inc. Outrun the Sun is partnering with the D
- Lambrolizumab Designated as Breakthrough Therapyhttps://practicaldermatology.com/news/20130429-lambrolizumab_designated_as_breakthrough_therapy/2459556/Merck & Co. received breakthrough therapy designation from the US Food and Drug Administration for its lambrolizumab drug as a treatment of patients with advanced melanoma. Lambrolizumab is Merck's investigational antibody therapy targeting Programm